228 related articles for article (PubMed ID: 37490356)
1. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K
Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356
[TBL] [Abstract][Full Text] [Related]
2. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
[TBL] [Abstract][Full Text] [Related]
3. Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
Adamec I; Brecl Jakob G; Rajda C; Drulović J; Radulović L; Bašić Kes V; Lazibat I; Rimac J; Cindrić I; Gržinčić T; Abičić A; Barun B; Gabelić T; Gomezelj S; Mesaroš Š; Pekmezović T; Klivényi P; Krbot Skorić M; Habek M
J Neuroimmunol; 2023 Sep; 382():578164. PubMed ID: 37536052
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
[TBL] [Abstract][Full Text] [Related]
5. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
Brownlee W; Amin A; Ashton L; Herbert A
Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
Brownlee WJ; Haghikia A; Hayward B; Waser N; Kayaniyil S; Khan Z; Duncan J; Millar S; Harty GT
Mult Scler Relat Disord; 2023 Aug; 76():104791. PubMed ID: 37343465
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Keller B; Jack D; Vermersch P
Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
[TBL] [Abstract][Full Text] [Related]
8. High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
Negrotto L; Iut VC; Etchepare A; D'Eramo M; Grinspan A; Assefi A
Mult Scler Relat Disord; 2022 Dec; 68():104403. PubMed ID: 36544327
[TBL] [Abstract][Full Text] [Related]
9. Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4.
Magalashvili D; Mandel M; Dreyer-Alster S; Didikin M; Harari G; Flechter S; Achiron A
J Neuroimmunol; 2022 Nov; 372():577966. PubMed ID: 36162338
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort.
Aerts S; Khan H; Severijns D; Popescu V; Peeters LM; Van Wijmeersch B
Mult Scler Relat Disord; 2023 Jul; 75():104735. PubMed ID: 37192586
[TBL] [Abstract][Full Text] [Related]
11. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
Zanetta C; Rocca MA; Meani A; Martinelli V; Ferrè L; Moiola L; Filippi M
J Neurol; 2023 Jul; 270(7):3553-3564. PubMed ID: 37027018
[TBL] [Abstract][Full Text] [Related]
13. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
14. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
15. Cladribine Tablets: A Review in Relapsing MS.
Deeks ED
CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
[TBL] [Abstract][Full Text] [Related]
16. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
Alroughani R; Al-Hashel J; Ahmed SF
Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
[TBL] [Abstract][Full Text] [Related]
17. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis.
Terranova N; Hicking C; Dangond F; Munafo A
Clin Pharmacokinet; 2019 Mar; 58(3):325-333. PubMed ID: 29992396
[TBL] [Abstract][Full Text] [Related]
18. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Giovannoni G; Singer BA; Issard D; Jack D; Vermersch P
Mult Scler; 2022 Jul; 28(8):1219-1228. PubMed ID: 34634968
[TBL] [Abstract][Full Text] [Related]
19. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Pinheiro B; Guerreiro R; Costa J; Miguel LS
J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
[No Abstract] [Full Text] [Related]
[Next] [New Search]
